Table 1.
Demographic, clinical and immunological characteristics of the patients with SSc (n = 134, 100%)
| Variable | Result |
|---|---|
| Age at SSc onset (years) | 38.5 (± 15.7) |
| Age at NVC (years) | 54.7 (± 14.4) |
| Cutaneous subsets, dcSSc/lcSSc/ssSSc | 28 (20.9)/88 (65.7)/18 (13.4) |
| Time elapsed from first symptom to NVC (years) | 16.0 (± 12.6) |
| Time elapsed from first non-RP symptom to NVC (years) | 10.9 (± 9.9) |
| 2013 ACR/EULAR SSc classification criteria fulfilment | 121 (90.2) |
| ACA/ATA/anti-RNA pol III/anti-PM/Scl | 49 (36.6)/31 (23.1)/14 (10.4)/11 (8.2) |
| Raynaud’s phenomenon | 132 (98.5) |
| Telangiectasias | 97 (72.4) |
| Digital ulcers | 62 (46.3) |
| Calcinosis | 29 (21.6) |
| Scleroderma renal crisis | 2 (1.5) |
| Interstitial lung disease | 58 (43.3) |
| Pulmonary arterial hypertension | 11 (8.2) |
| Cardiac involvement | 103 (76.9) |
| Musculoskeletal disease | 40 (29.9) |
| Gastrointestinal involvement | 110 (82.1) |
| Overlap features | 19 (14.1) |
Data presented as mean (± standard deviation) for continuous variables and as number (%) for categorical variables
SSc systemic sclerosis, NVC nailfold videocapillaroscopy, dcSSc diffuse cutaneous systemic sclerosis, lcSSc limited cutaneous systemic sclerosis, ssSSc sine scleroderma systemic sclerosis, RP Raynaud’s phenomenon, ACR American College of Rheumatology, EULAR European League Against Rheumatism, ACA anticentromere antibodies, ATA anti-topoisomerase I